Dragonfly and Celgene Extended their Collaboration from 2017- for the Treatment of Solid and Hematological Cancers
Shots:
- Celgene has added four more immunotherapies (making it eight- to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product- using Dragonfly’s TriNKET technology
- Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene)
- TriNKET technology (Tri-specific- NK cell Engager Therapeutics) uses NK cells- for developing immunotherapies for cancer
Ref: PRNewsWire| Image: The Street
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
